Mortimer JE, Bading JR, Park JM, Frankel PH, Carroll MI, Tran TT, et al. Tumor uptake of (64)Cu-DOTA-Trastuzumab in patients with metastatic breast cancer. J Nucl Med. 2018;59:38–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marquez BV, Ikotun OF, Zheleznyak A, Wright B, Hari-Raj A, Pierce RA, et al. Evaluation of (89)Zr-pertuzumab in breast cancer xenografts. Mol Pharm. 2014;11:3988–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo X, Zhou N, Chen Z, Liu T, Xu X, Lei X, et al. Construction of (124)I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients. Gastric Cancer. 2020;23:614–26.

Article  CAS  PubMed  Google Scholar 

Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, et al. Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J Nucl Med. 2016;57:27–33.

Article  CAS  PubMed  Google Scholar 

Lockhart AC, Liu Y, Dehdashti F, Laforest R, Picus J, Frye J. Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors. Mol Imaging Biol. 2016;18:446–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN, Terwisscha van Scheltinga AGT, et al. (89)Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors. Clin Cancer Res. 2017;23:6128–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang Y, Hu Y, Liu W, Chen L, Zhao Y, Ma H, et al. A radiopharmaceutical [(89)Zr]Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo. Nucl Med Biol. 2019;70:23–31.

Article  CAS  PubMed  Google Scholar 

Stone LD, Massicano AVF, Stevens TM, Warram JM, Morlandt AB, Lapi SE, et al. (89)Zr-panitumumab PET imaging for preoperative assessment of ameloblastoma in a PDX model. Sci Rep. 2022;12:19187.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Loon J, Even AJG, Aerts H, Ollers M, Hoebers F, van Elmpt W, et al. PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer. Radiother Oncol. 2017;122:267–73.

Article  PubMed  Google Scholar 

Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852–8.

Article  CAS  PubMed  Google Scholar 

He H, Qi X, Fu H, Xu J, Zheng Q, Chen L. Imaging diagnosis and efficacy monitoring by [89Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies. Theranostics. 2024;14(1):392–405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kok IC, Hooiveld JS, van de Donk PP, Giesen D, van der Veen EL, Lub-de Hooge MN, et al. (89)Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer. Ann Oncol. 2022;33:80–8.

Article  CAS  PubMed  Google Scholar 

Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O’Donoghue JA, et al. First-in-humans imaging with (89)Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting. J Nucl Med. 2020;61:512–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shuch B, Pantuck AJ, Bernhard JC, Morris MA, Master V, Scott AM, et al. [89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024;25:1277–87.

Article  CAS  PubMed  Google Scholar 

Pandit-Taskar N, O’Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, et al. (8)(9)Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:2093–105.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pandit-Taskar N, O’Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, et al. First-in-human imaging with 89Zr-Df-IAB2M anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake. J Nucl Med. 2016;57:1858–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guleria M, Sharma R, Amirdhanayagam J, Sarma HD, Rangarajan V, Dash A, et al. Formulation and clinical translation of [(177)Lu]Lu-trastuzumab for radioimmunotheranostics of metastatic breast cancer. RSC Med Chem. 2021;12(2):263–77.

Article  CAS  PubMed  Google Scholar 

Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, et al. Safety and Outcome Measures of First-in-Human Intraperitoneal alpha Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. Am J Clin Oncol. 2018;41:716–21.

Article  CAS  PubMed  Google Scholar 

Chevallier P, Eugene T, Robillard N, Isnard F, Nicolini F, Escoffre-Barbe M, et al. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematol. 2015;2:e108–17.

Article  PubMed  Google Scholar 

Shen S, Forero A, Meredith RF, Shah JJ, Knox SJ, Wiseman GA, et al. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma. J Nucl Med. 2010;51(1):150–7.

Article  CAS  PubMed  Google Scholar 

Rosenblat TL, McDevitt MR, Carrasquillo JA, Pandit-Taskar N, Frattini MG, Maslak PG, et al. Treatment of patients with acute myeloid leukemia with the targeted alpha-particle nanogenerator Actinium-225-Lintuzumab. Clin Cancer Res. 2022;28:2030–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, et al. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2020;4(17):4091–101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Börjesson PKE, Postema EJ, Roos JC, Colnot DR, Marres HAM, van Schie MH, et al. Phase I therapy study with 186Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2003;9:12.

Google Scholar 

Muselaers CH, Boers-Sonderen MJ, van Oostenbrugge TJ, Boerman OC, Desar IM, Stillebroer AB, et al. Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2016;69:767–70.

Article  CAS  PubMed  Google Scholar 

Kramer K, Humm JL, Souweidane MM, Zanzonico PB, Dunkel IJ, Gerald WL, et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol. 2007;25:5465–70.

Article  PubMed  Google Scholar 

Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scott AM, Wiseman G, Welt S, Adjei A, Lee F-T, Hopkins W, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9:9.

Google Scholar 

Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol. 2005;23:6763–70.

Article  CAS  PubMed  Google Scholar 

Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: concept, design, and applications. Chem Rev. 2020;120:3787–851.

Article  CAS